Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center...
MD Anderson, the Oden Institute and TACC announce funding for six new collaborative cancer projects
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing...
MD Anderson Research Highlights for November 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson receives nearly $8 million in CPRIT funding for screening and early detection programs, faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded nearly $8 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of faculty recruitment as well as lung and colorectal cancer screening and early detection programs to address cancer incidence rates across Texas.
“CPRIT’s continued support is essential for progress in our mission to end cancer, and we appreciate this important funding...
Healthy women have cells that resemble breast cancer, study finds
A new study from researchers at The University of Texas MD Anderson Cancer Center finds that, in healthy women, some breast cells that otherwise...
MD Anderson Research Highlights: SITC 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation,...
Jennifer Bickel, M.D., named MD Anderson Vice President and Chief Wellness Officer
The University of Texas MD Anderson Cancer Center today announced the selection of Jennifer Bickel, M.D., as the institution’s inaugural vice...